Biotechnology News and Research

RSS

Arcion receives U.S. patent allowance for ARC-2022 to treat PHN

Arcion Therapeutics, a clinical stage biotechnology company developing topical therapies for chronic pain, today announced that it received notice of allowance for a US Patent for its high strength gel formulation of topical lidocaine, ARC-2022.

5 Jan 2012

Scientists determine structure of endomannosidase enzyme

Scientists have determined the structure of the enzyme endomannosidase, significantly advancing our understanding of how a group of devastating human viruses including HIV and Hepatitis C hijack human enzymes to reproduce and cause disease.

4 Jan 2012

AAIPharma announces acquisition of Celsis Analytical Services

AAIPharma Services Corp., a leading provider of pharmaceutical product development services, announced today it has acquired Celsis Analytical Services, a division of Celsis International Ltd. that performs material testing services for the pharmaceutical, biotechnology and manufacturing sectors.

4 Jan 2012

NovaSterilis awarded soft tissue processing patent

NovaSterilis Inc., specializing in developing applications for supercritical carbon dioxide, has been granted US Patent 8,034,288 B2. The patent, dated October 11, 2011 entitled “Method and Apparatus for Cleaning of Viable Donor Soft Tissue”, covers a new method for cleaning soft allograft tissue including tendon, fascia, and skin with a supercritical fluid, thus avoiding other harmful chemical solvents that may leave residual chemicals.

4 Jan 2012

MTR technique indicates that COPAXONE therapy results in tissue repair in RRMS patients

Researchers utilizing an advanced magnetic resonance imaging (MRI) technology to characterize and chart the evolution of MS lesions found that relapsing-remitting multiple sclerosis (RRMS) patients treated with COPAXONE (glatiramer acetate injection) experienced significantly increased magnetization transfer ratio.

4 Jan 2012

Antigen Express to move AE37 cancer vaccine into larger clinical trials

Generex Biotechnology Corporation today provided an update to the clinical development & regulatory strategy for its cancer vaccine, AE37.

4 Jan 2012

BioTime to market muscle progenitor cell lines bearing hereditary diseases

BioTime, Inc. today announced that it has elected to market progenitors of muscle stem cells bearing hereditary diseases. BioTime will produce the products from five human embryonic stem (hES) cell lines from Reproductive Genetics Institute (RGI) of Chicago, Illinois.

4 Jan 2012

FDA issues PMA response letter to BioMimetic's Augment Bone Graft

BioMimetic Therapeutics, Inc. announced today that it received a comprehensive post-panel response letter from the FDA related to the Company's Pre-Market Approval (PMA) application for Augment Bone Graft for use as an alternative to autograft in hindfoot and ankle fusion procedures.

4 Jan 2012

Positive results from Can-Fite BioPharma's CF102 Phase 1/2 study on HCC

Can-Fite BioPharma Ltd, a biotechnology company developing small molecule drugs for the treatment of inflammatory, and liver diseases, traded on the Tel Aviv Stock Exchange announced today the successful results of the Phase 1/2 study of its drug candidate CF102 in the treatment of hepatocellular carcinoma.

4 Jan 2012

Accelrys announces acquisition of VelQuest

Accelrys, Inc., a leading scientific enterprise research and development software and services company, today announced that it has acquired privately-held VelQuest Corporation for $35 million in an all-cash transaction.

3 Jan 2012

RBCC: 2012 could turn out to be better for the global biotechnology sector

With strong growth predicted for the biotech and pharmaceuticals industry in 2012, emerging biotech firm Rainbow Coral Corp. anticipates a prosperous new year ahead.

31 Dec 2011

Additional financing to fund Advaxis' cervical cancer trials

Advaxis, Inc.,, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has entered into a definitive Convertible Notes Purchase Agreement (Agreement) with certain accredited investors, for the purchase of the aggregate principal value of approximately $1.2 million of Convertible Promissory Notes (Notes) for an aggregate purchase price of approximately $1.0 million.

31 Dec 2011

FDA invites Amgen for ODAC meeting on XGEVA sBLA to treat castration-resistant prostate cancer

Amgen today announced the U.S. Food and Drug Administration has invited the Company to participate in a meeting of the Oncologic Drugs Advisory Committee (ODAC) on Feb. 8, 2012 to discuss the supplemental Biologics License Application (sBLA) for XGEVA (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases.

30 Dec 2011

Alexion to acquire 100% of capital stock of Enobia

Alexion Pharmaceuticals, Inc. and Enobia Pharma Corp. today announced that the companies have signed a definitive agreement under which Alexion will acquire 100% of the capital stock of Enobia.

29 Dec 2011

Nano3D's technology and revenues continue to impress RBCC

As Rainbow Coral Corp. continues its due diligence on Nano3D Biosciences (n3D), it's not just the early-stage biotech firm's groundbreaking technology that has impressed RBCC—It's also n3D's revenues.

28 Dec 2011

Initial results from 22nd Century's X-22 Phase II-B smoking cessation trial

22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction products, today announced X-22, a prescription smoking cessation aid in development consisting of very low nicotine (VLN) cigarettes, showed a reduction of smoking from baseline over the 6-week treatment period in the company's Phase II-B clinical trial.

26 Dec 2011

Momenta, Baxter partner to develop and commercialize biosimilars

Baxter International Inc. and Momenta Pharmaceuticals, Inc. today announced that they have entered into a global collaboration to develop and commercialize follow-on biologic products, also known as biosimilars.

From Baxter International Inc. 23 Dec 2011

Inhibition of necroptosis protects mice from lethal SIRS

Sepsis, a form of systemic inflammation, is the leading cause of death in critically ill patients. Sepsis is linked with massive cell death; however, the specific mechanisms involved in the lethality of sepsis are unclear. Now, a new study published by Cell Press in the December 23rd issue of the journal Immunity finds that inhibition of a specific cell death pathway called "necroptosis" protected mice from lethal inflammation.

23 Dec 2011

Virus with potential for bioterrorism created – Experts worried

Two major scientific journals are debating on whether to publish details of a man-made mutant flu virus that could kill billions, after a US government's science advisory committee advised them to withhold key details.

21 Dec 2011

Antihypertensive drug therapy associated with longer life expectancy

More than 68 percent of Americans 65 and older - 80 percent age 75 and over - have hypertension (high blood pressure), according to a 2010 report by the Centers for Disease Control. Left untreated, this chronic condition can lead to stroke, heart attack, heart failure or premature death. Researchers at UMDNJ-Robert Wood Johnson Medical School have shown in a follow-up to the landmark clinical trial, Systolic Hypertension in the Elderly Program (SHEP), that the use of antihypertensive drug therapy is associated with longer life expectancy.

21 Dec 2011